

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Spectral Neuroscience Inc.	06/28/2007
RECEIVING PARTY DATA	
Name:	Novartis International Pharmaceuticals Ltd.
Street Address:	Hurst Home, 12 Trott Road
City:	Hamilton
State/Country:	BERMUDA
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6291175
CORRESPONDENCE DATA	
Fax Number:	(973)781-8064
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	cindy.klepacky@novartis.com
Correspondent Name:	Cindy Klepacky
Address Line 1:	One Health Plaza
Address Line 4:	East Hanover, NEW JERSEY 07936
ATTORNEY DOCKET NUMBER:	52221-US-NP
NAME OF SUBMITTER:	Cindy Klepacky
Total Attachments: 7 source=Spectral Neuroscience Inc. to Novartis#page1.tif source=Spectral Neuroscience Inc. to Novartis#page2.tif source=Spectral Neuroscience Inc. to Novartis#page3.tif source=Spectral Neuroscience Inc. to Novartis#page4.tif source=Spectral Neuroscience Inc. to Novartis#page5.tif source=Spectral Neuroscience Inc. to Novartis#page6.tif source=Spectral Neuroscience Inc. to Novartis#page7.tif	

CH \$40.00 6291175

PATENT

ASSIGNMENT

For valuable consideration, we,

Full Name of Assignor	State of Incorporation	Business Address
Spectral Neuroscience Inc.	Quebec	1501 McGill College 26 th Floor Montreal, Québec, Canada, H3A 3N9

hereby assign to

Full Name of Assignee	State of Incorporation	Business Address
Novartis International Pharmaceutical Ltd.	Bermuda	Hurst Home, 12 Trott Road Hamilton, HM 11 Bermuda

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are the subject of one or more of the patents and applications listed on Schedule A, which is attached hereto.

This assignment includes the patents and applications listed in the attached Schedule A, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of any of the patents and applications listed in the attached Schedule A under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

IN WITNESS WHEREOF, I hereto set my hand and seal at 3015 BIRKING, Q.C., CANADA
this 22 day of JUNE, 2007

Spectral Neuroscience Inc. L.S.

PROVINCE
STATE OF QUEBEC :
COUNTRY CANADA :
COUNTY OF _____ :ss.

Before me this ____ day of _____, 20____, before me, the undersigned notary public, personally appeared _____, proved to me through satisfactory evidence of identification, which consisted of _____, to be the person whose name is subscribed to the foregoing Assignment, and acknowledged that he executed the same as his free act and deed for the purposes therein contained.

Notary Public

My Commission Expires:

[Notary's Seal Here]



Schedule A

Title	First Named Inventor	Application No.	Filed	Patent No.	Issued
APOLIPOPROTEIN E POLYMORPHISM AND TREATMENT OF ALZHEIMER'S DISEASE	Judes Poirier	08/727,637	02/21/97	5,935,781	08/10/99
APOLIPOPROTEIN E POLYMORPHISM AND TREATMENT OF ALZHEIMER'S DISEASE	Judes Poirier	09/342,993	06/29/99	7,049,078	05/23/06
METHODS FOR ASSESSING THE PROGNOSIS OF A PATIENT WITH A NEURODEGENERATIVE DISEASE	Judes Poirier	08/766,975	12/16/96	6,022,683	02/08/00
PHARMACOGENETIC METHODS FOR USE IN THE TREATMENT OF NERVOUS SYSTEM DISEASES	Judes Poirier	09/500,162	02/08/00	7,001,736	02/21/06
METHODS FOR ASSESSING THE PROGNOSIS OF A PATIENT WITH A NEURODEGENERATIVE DISEASE	Judes Poirier	09/865,753	05/25/01		
METHOD FOR DETERMINING THE PROGNOSIS OF A PATIENT WITH A NEUROLOGICAL DISEASE	Pierre Sevigny	08/991,850	12/16/97	6,251,587	06/26/01
METHOD FOR DETERMINING THE PROGNOSIS OF A PATIENT WITH A NEUROLOGICAL DISEASE	Pierre Sevigny	09/548,540	04/13/00		
METHODS FOR TREATING A NEUROLOGICAL DISEASE BY DETERMINING BCHE GENOTYPE	Pierre Sevigny	60/089,406	06/16/98		
METHODS FOR TREATING A NEUROLOGICAL DISEASE BY DETERMINING BCHE GENOTYPE	Pierre Sevigny	09/334,489	06/16/99	6,291,175	09/18/01

APOLIPOPROTEIN E POLYMORPHISM AND TREATMENT OF ALZHEIMER'S DISEASE

Country	First Named Inventor	Application No.	Filed	Patent No.	Issued
Australia	Judes Poirier	23006/95	04/26/95	693193	11/05/98
Australia	Judes Poirier	87009/98	04/26/95	733237	04/26/99
Canada	Judes Poirier	2,188,933	04/26/95	2,188,933	04/26/96
Europe	Judes Poirier	95916530.9	04/26/95	0804615	08/20/03
Finland	Judes Poirier	95916530.9	04/26/95	964284	08/20/03
France	Judes Poirier	95916530.9	04/26/95	0804615	08/20/03
Germany	Judes Poirier	69531537.9-08	04/26/95	0804615	08/20/03
Japan	Judes Poirier	7-527248	04/26/95	3,285,585	03/08/02
Mexico	Judes Poirier	965176	04/26/95		
New Zealand	Judes Poirier	284412	04/26/95	284412	04/26/00
New Zealand	Judes Poirier	500375	04/26/95	500375	10/09/01
Norway	Judes Poirier	19964543	04/26/95		
PCT	Judes Poirier	CA95-00240	04/26/95		
Singapore	Judes Poirier	9611756-9	04/26/95	34770	03/20/98
United Kingdom	Judes Poirier	95916530.9	04/26/95		

PHARMACOGENETIC METHODS FOR USE IN THE
TREATMENT OF NERVOUS SYSTEM DISEASES

Country	First Named Inventor	Application No.	Filed	Patent No.	Issued
Australia	Judes Poirier	56757/98	12/16/97	745073	03/14/02
Canada	Judes Poirier	2,275,504	12/16/97		
Europe	Judes Poirier	97953011.0	12/16/97	0946753	06/09/04
France	Judes Poirier	97953011.0	12/16/97	0946753	06/09/04
Germany	Judes Poirier	69729473.0	12/16/97	0946753	06/09/04
Japan	Judes Poirier	Hei 10-527507	12/16/97		
PCT	Judes Poirier	IB97/01648	12/16/97		
United Kingdom	Judes Poirier	97953011.0	12/16/97	0946753	06/09/04

METHOD FOR DETERMINING THE PROGNOSIS OF
A PATIENT WITH A NEUROLOGICAL DISEASE

Country	First Named Inventor	Application No.	Filed	Patent No.	Issued
Australia	Pierre Seigny	55717/98	12/16/97		
Canada	Pierre Seigny	2,275,404	12/16/97		
Europe	Pierre Seigny	97982129.1	12/16/97	0948647	06/23/04
France	Pierre Seigny	97982129.1	12/16/97	0948647	06/23/04
Germany	Pierre Seigny	69729654.7	12/16/97	0948647	06/23/04
PCT	Pierre Seigny	IB97/01641	12/16/97		
United Kingdom	Pierre Seigny	97982129.1	12/16/97	0948647	06/23/04

METHODS FOR TREATING A NEUROLOGICAL
DISEASE BY DETERMINING BCHE GENOTYPE

Country	First Named Inventor	Application No.	Filed	Patent No.	Issued
Australia	Pierre Sevigny	45292/99	06/16/99		
Canada	Pierre Sevigny	2,330,829	06/16/99		
Europe	Pierre Sevigny	99928180.1	06/16/99	1088104	02/08/06
France	Pierre Sevigny	99928180.1	06/16/99	1088104	02/08/06
Germany	Pierre Sevigny	69929787.7-08	06/16/99	1088104	02/08/06
Italy	Pierre Sevigny	99928180.1	06/16/99	1088104	02/08/06
Japan	Pierre Sevigny	2000-554880	06/16/99		
PCT	Pierre Sevigny	IB99-01298	06/16/99		
United Kingdom	Pierre Sevigny	99928180.1	06/16/99	1088104	02/08/06

HP OfficeJet G Series G85
Imprimante/télécopieur/copieur/numériseur

Rapport historique télécopies pour
Techno Synapse Inc
450-437-5775
Jun 28 2007 7:26pm

Dernière télécopie

<u>Date</u>	<u>Heure</u>	<u>Type</u>	<u>Identification</u>	<u>Durée</u>	<u>Pages</u>	<u>Résultat</u>
Jun 28	7:24pm	Envoyé	16174287045	2:06	7	OK

Résultat:

OK - télécopie noir et blanc
Couleur Ok - télécopie couleur